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Objective. The assessment of disease activity in
Takayasu arteritis (TA) is difficult in clinical situations
because clinical symptoms and laboratory parameters
do not always reflect the actual inflammation of the
arterial wall. We undertook this study to comprehen-
sively investigate the role of 18F-fluorodeoxyglucose–
positron emission tomography (FDG-PET) in the as-
sessment of disease activity in patients with TA.
Methods. We performed a retrospective chart
review of 53 FDG-PET scans in 38 patients with TA. We
measured 18F-fluorodeoxyglucose (18F-FDG) accumula-
tion in the vascular wall of the large vessel using
semiquantitative (visual grade) and quantitative (stan-
dard uptake value intensity) analyses. Clinical disease
activity was evaluated based on the National Institutes
of Health criteria for active TA, and erythrocyte sedi-
mentation rates (ESRs) and C-reactive protein (CRP)
levels were measured.
Results. At baseline, active vascular 18F-FDG
uptake (visual grade >2) was observed in 18 of 24
patients with active disease and in 5 of 14 patients with
inactive disease. There was a significant association
between clinical disease activity and disease activity
judged by FDG-PET (P 0.008). Visual grade, standard
uptake value intensity, and the number of vascular
lesions with active 18F-FDG uptake were significantly
higher in patients with active disease and correlated
well with the ESR and CRP levels. In 15 followup
FDG-PET scans, the changes in visual grade, areas of
active vascular 18F-FDG uptake, and standard uptake
value intensity reflected changes in clinical disease
activity.
Conclusion. 18F-FDG uptake was associated with
clinical disease activity and markers of inflammation,
and FDG-PET reflected changes in clinical disease
activity in patients with TA. FDG-PET may be a useful
tool for aiding in the assessment of disease activity in
patients with TA.
Takayasu arteritis (TA) is a chronic inflammatory
disease of the large arteries, primarily affecting the aorta
and its main branches. Diagnosis of TA usually relies on
postinflammatory sequels, such as narrowing, stenosis,
or aneurysm of large vessels. Therefore, it is difficult to
treat the potentially reversible early inflammation of TA
before vascular insufficiencies occur. It is important to
detect inflammation in the arterial wall early in the
disease course and to treat it before irreversible struc-
tural changes occur. A sensitive and useful method is
necessary for the diagnosis of early inflammation and for
following disease activity in TA. However, assessment of
disease activity in TA is difficult in clinical situations
because the clinical symptoms and laboratory para-
meters do not always adequately reflect the actual
inflammation of the arterial wall (1,2), and, as of now, no
adequate surrogate is available for assessing disease
activity in TA. Imaging modalities such as computed
tomography (CT) and magnetic resonance imaging
(MRI) reveal anatomic inflammatory changes of the
affected arterial wall and have been suggested for mon-
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itoring disease activity of TA (3), but have not shown
consistent correlation with disease activity (4–7).
18F-fluorodeoxyglucose–positron emission tomo-
graphy (FDG-PET) is an imaging modality that visual-
izes the metabolic status of the body. It detects pairs of
gamma rays emitted by 18F-fluorodeoxyglucose (18F-
FDG), a positron-emitting radionuclide, taken up by
cells with active metabolism such as malignant or inflam-
matory cells. Studies have shown the role of FDG-PET
in diagnosing and monitoring TA, but there is some
controversy regarding its ability to assess disease activity
(8–15). Several studies showed that FDG-PET correctly
detected active inflammation in the arterial wall of
patients with TA, and that 18F-FDG uptake decreased as
disease activity improved (9–14). However, a recent
study showed a lack of correlation between 18F-FDG
uptake and both clinical disease activity and markers of
inflammation (8). Previous studies of the utility of
FDG-PET had relatively small numbers of FDG-PET
scans, mainly due to the rarity of TA (9–14). In this
study, we investigated the role of FDG-PET in the
assessment of TA disease activity in a relatively large
cohort of patients with TA.
PATIENTS AND METHODS
Between December 2002 and January 2010, 38 consec-
utive patients diagnosed as having TA agreed to undergo at
least 1 FDG-PET scan at Severance Hospital in Seoul, South
Korea. FDG-PET scans were performed to evaluate baseline
disease activity and to evaluate patients in whom disease
activity was uncertain based on clinical and laboratory findings.
We analyzed a total of 53 FDG-PET scans performed on these
patients from July 2003 to February 2010; the median time
from diagnosis of TA to the FDG-PET scan was 11 months
(range 1–348 months). All of the patients met the American
College of Rheumatology 1990 classification criteria for TA
(16). We permitted the substitution of conventional angio-
graphy with either CT angiography or MR angiography, based
on literature reporting the accuracy of CT and MRI in the
diagnosis of TA (17–19). Approval by our institutional review
board was obtained, and the requirement for informed consent
was waived as this study was considered a diagnostic procedure
with benefits for the patients.
PET examination. FDG-PET images were acquired
using a whole-body tomography scanner (Allegro; Philips).
This scanner provided a 57.6-cm axial field of view and an
18.5-cm transaxial field of view, which produced 46 image
planes spaced 4.02 mm apart. The transaxial spatial resolution
was 4.2 mm full width at half maximum at the center of the
field of view, and the axial resolution was 5.0 mm full width at
half maximum. The patients fasted for at least 6 hours before
intravenous injection of 370 MBq (10 mCi) 18F-FDG, and the
mean serum glucose level was 92.9 mg/dl (range 74–122) just
before injection. A whole-body emission scan was obtained in
all patients 40–60 minutes after injection using the multiple-
bed position technique. Seven to 8 bed positions from the
external acoustic meatus to the thigh were imaged for 4
minutes per bed position. All patients were studied in the
supine position with their arms alongside their bodies.
Attenuation-corrected transaxial images were reconstructed
with an iterative transmission algorithm called Row-Action
Maximum-Likelihood 3D protocol using a 3-dimensional
(3-D) image filter into a 128  128 matrix.
Analysis of FDG-PET images. FDG-PET scan images
were displayed on coronal, transaxial, and sagittal planes and
with rotating 3-D images. They were reviewed by 2 indepen-
dent nuclear physicians (AC, Y-JC) who were blinded to the
clinical disease activity corresponding to each scan. In cases of
disagreement, the final interpretation was determined by con-
sensus between the 2 nuclear physicians after an additional
review. Visual analysis was performed on 11 vascular regions:
ascending aorta, aortic arch, right innominate artery, right
subclavian artery, right common carotid artery, left common
carotid artery, left subclavian artery, descending thoracic
aorta, abdominal aorta, right common iliac artery, and left
common iliac artery.
We used 2 parameters to measure 18F-FDG uptake
values, visual grade and standard uptake value intensity. Visual
grade is a semiquantitative measurement of 18F-FDG activity,
where 0  no vascular uptake, 1  vascular uptake less than
liver uptake, 2  vascular uptake similar to liver uptake, and
3  vascular uptake greater than liver uptake. Active vascular
18F-FDG uptake was defined as grade 2. For quantitative
measurement of 18F-FDG uptake, we obtained the standard
uptake value, defined as the ratio of 18F-FDG activity to the
injected 18F-FDG activity divided by the body mass index, from
the region of interest (ROI) of each vascular region. In order
to minimize the effect of time from injection to acquisition and
to minimize the effect of blood glucose levels, we divided the
standard uptake value of a vascular ROI with the maximal
standard uptake value of the liver and named this value
“standard uptake value intensity.” For the selection of a
representative value of the 18F-FDG uptake of an FDG-PET
scan, we selected 1 vascular ROI with the most intense
18F-FDG uptake and measured it using both semiquantitative
(visual grade) and quantitative (standard uptake value inten-
sity) methods.
Assessment of clinical disease activity. When perform-
ing FDG-PET scans, we assessed the clinical disease activity in
each patient on the basis of the National Institutes of Health
(NIH) criteria for active disease in TA (1). TA was considered
to be active when the patient experienced new development or
worsening of 2 of the following: 1) systemic features (such as
fever or musculoskeletal features) with no other cause identi-
fied, 2) elevated erythrocyte sedimentation rate (ESR), 3)
features of vascular ischemia or inflammation, such as claudi-
cation, diminished or absent pulses, bruit, vascular pain (caro-
todynia), and asymmetric blood pressure in the upper or lower
limbs (or both), and 4) typical angiographic features. Due to
heterogeneity in the angiographic modalities, the definition of
worsening of angiographic features was confined to the wors-
ening of luminal changes in the affected vessel. The median
duration between previous clinical evaluation and evaluation
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at the time of FDG-PET scanning was 3 months (range 1–5
months). Patients with inactive disease were defined as those
who did not meet the NIH criteria for active TA.
Markers of inflammation. ESRs and C-reactive pro-
tein (CRP) levels were measured when FDG-PET was per-
formed. ESR was measured by the modified Westergren
method, and CRP level was measured by nephelometry
(IMMAGE; Beckman Coulter). The normal range of ESR was
defined as 0–15 mm/hour for male patients and 0–20 mm/hour
for female patients. Increased CRP level was defined as a value
0.8 mg/dl.
Statistical analysis. We used SPSS software, version
15.0. A weighted kappa statistic was used to assess the degree
of agreement between the 2 nuclear physicians. The Mann-
Whitney U test was used to compare continuous variables in
the groups with clinically active and inactive disease. The
chi-square test was used to assess the association between
clinical disease activity and disease activity judged by FDG-
Table 1. Baseline values of clinical disease activity, laboratory markers, and 18F-FDG uptake*
Patient/age/sex
ESR,
mm/hour
CRP,
mg/dl
Clinical disease
activity
PET disease
activity†
Visual
grade‡
SUV
intensity§
Lesions with active
18F-FDG uptake¶
1/37/F 29 NA Yes Yes 3 1.25 1–3, 5, 8–10
2/38/F 26 0.41 Yes Yes 3 1.00 1, 2, 4–11
3/42/F 70 5.38 Yes Yes 2 1.01 1
4/33/F 50 4.91 Yes Yes 3 1.41 1–11
5/41/F 45 1.81 Yes Yes 3 1.78 1, 3–6, 8–11
6/45/F 29 0.43 Yes Yes 3 1.23 1–4, 6, 8
7/56/F 24 0.50 Yes Yes 3 0.96 2, 3, 5, 6, 8
8/23/F 120 2.33 Yes Yes 3 2.36 1–11
9/25/F 26 1.10 Yes Yes 2 0.90 1, 2, 8
10/45/F 26 2.09 Yes No 1 0.80 –
11/64/F 36 0.60 Yes Yes 3 1.45 1, 8, 9
12/32/F 88 1.56 Yes Yes 3 1.14 1–7, 9–11
13/23/F 44 0.34 Yes Yes 3 1.07 1–3, 6, 7
14/39/F 30 0.38 Yes No 1 1.10 –
15/58/F 10 0.20 Yes No 1 0.78 –
16/53/F 8 0.94 Yes No 1 0.86 –
17/28/F 2 0.10 Yes Yes 2 0.96 1
18/67/M 22 0.17 Yes No 1 0.79 –
19/40/M 64 1.33 Yes Yes 3 0.72 1–6, 8–11
20/57/F 19 0.20 Yes No 1 0.71 –
21/38/F 44 0.12 Yes Yes 2 0.94 8
22/48/F 36 0.10 Yes Yes 3 1.47 1, 2, 6, 8
23/43/F 17 0.49 Yes Yes 3 1.73 1, 4, 5, 8, 9, 11
24/29/F 38 0.49 Yes Yes 2 0.91 1, 2, 4, 5, 8–11
25/49/F 20 0.10 No No 1 0.78 –
26/55/F 14 0.14 No No 1 0.78 –
27/55/F 44 0.18 No Yes 2 0.88 5
28/59/F 4 0.10 No No 1 0.56 –
29/50/F 39 0.19 No No 1 0.8 –
30/49/F 26 0.10 No No 1 0.78 –
31/44/M 2 0.13 No Yes 2 0.80 1, 2
32/26/F 61 2.41 No No 1 0.74 –
33/52/F 23 0.27 No Yes 2 0.95 1, 2, 8
34/41/F 48 0.14 No No 1 0.84 –
35/48/F 47 0.725 No No 1 0.73 –
36/26/M 4 0.21 No No 1 0.82 –
37/45/F 14 0.10 No Yes 2 0.83 1
38/36/F 12 0.21 No Yes 2 0.71 1, 2, 6, 8
* 18F-FDG  18F-fluorodeoxyglucose; ESR  erythrocyte sedimentation rate; CRP  C-reactive protein; NA  not available.
† Disease activity of Takayasu arteritis judged by 18F-fluorodeoxyglucose–positron emission tomography (FDG-PET), where an FDG-PET scan
shows at least 1 instance of active vascular 18F-FDG uptake (visual grade 2).
‡ Semiquantitative measure of 18F-FDG uptake, where 0  no vascular uptake, 1  vascular uptake less than liver uptake, 2  vascular uptake
similar to liver uptake, and 3  vascular uptake greater than liver uptake. The visual grade of a vascular region of interest (ROI) with maximal
18F-FDG uptake was selected.
§ Standard uptake value (SUV) intensity, defined as the ratio of maximal standard uptake value of a vascular ROI to the maximal standard uptake
value of liver at the 1 vascular ROI with the most intense 18F-FDG uptake.
¶ Vascular regions with visual grade values 2: 1  ascending aorta, 2  aortic arch, 3  right innominate artery, 4  right subclavian artery, 5 
right common carotid artery, 6  left common carotid artery, 7  left subclavian artery, 8  descending thoracic aorta, 9  abdominal aorta, 10 
right common iliac artery, 11  left common iliac artery.
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PET. The association between 18F-FDG uptake and ESR and
CRP level was assessed by Kruskal-Wallis test and Spearman’s
correlation in the case of visual grade and standard uptake
value intensity, respectively.
RESULTS
Baseline patient characteristics. A total of 38
patients were reviewed; 34 of them were female (89.5%).
Their mean SD age was 43.0 11.8 years. At the time
of diagnosis, these patients’ angiographic abnormalities
were revealed by digital subtraction angiography in 9
patients, CT angiography in 20, and MR angiography in
9. Followup imaging with the same modality used at the
time of diagnosis was performed in 28 patients 2 months
(range 0.5–7 months) before baseline FDG-PET scan-
ning. The median ESR value was 27.5 mm/hour (range
2–120) and the median CRP value was 0.26 mg/dl (range
0.1–5.38). Fifteen patients (39.5%) had discrepancies
between ESR and CRP values. Twenty-four patients
(63.2%) had clinically active disease. Among these 24
patients, the numbers fulfilling each NIH subcriterion
were 22 for increased ESR (91.7%), 8 for angiographic
features (33.3%), 7 for symptoms of vascular ischemia or
inflammation (29.2%), and 5 for systemic features
(20.8%). Twenty patients (83.3%) fulfilled 2 subcriteria,
and the other 4 patients (16.7%) fulfilled 3 subcriteria.
Analysis of the baseline FDG-PET scans. Thirty-
eight patients (4 males and 34 females) underwent 53
FDG-PET scans. Among these patients, 14 were receiv-
ing immunosuppressive drugs at the time of baseline
FDG-PET scanning. Among the 38 baseline FDG-PET
scans, 23 scans (60.5%) showed active vascular 18F-FDG
uptake (visual grade 2) in at least 1 vascular region. A
mean  SD 5.5  3.15 regions had active vascular
18F-FDG uptake. The ascending aorta (20 of 38 scans,
52.6%) and descending thoracic aorta (16 of 38 scans,
42.1%) were most commonly affected. Table 1 lists the
baseline values of clinical disease activity, laboratory
markers, and 18F-FDG uptake of each patient. The
weighted kappa score of interobserver agreement for the
semiquantitative classification was very good ( 
0.917).
Association with clinical disease activity. FDG-
PET correctly identified 18 of 24 patients with clinically
active disease (75%) and 9 of 14 patients with clinically
inactive disease (64.3%). There was a significant associ-
ation between clinical disease activity and disease activ-
ity judged by FDG-PET (P  0.008). There were 6
false-negative scan results and 5 false-positive scan
results. For clinically active disease, FDG-PET scans
showed a sensitivity of 75%, a specificity of 64.3%, a
positive predictive value (PPV) of 78.3%, and a negative
predictive value of 60%. Median (range) visual grade
(2.5 [1–3] versus 1 [1–2]; P  0.001), standard uptake
value intensity (1.01 [0.71–2.36] versus 0.79 [0.56–0.95];
P  0.001), and number of vascular lesions with active
18F-FDG uptake (4.5 [0–11] versus 1.72 [0–4]; P 
0.003) were significantly higher in patients with clinically
active disease than in those without (Table 2).
Association with laboratory markers. Visual grade
was significantly associated with the ESR (P  0.041)
and showed a trend toward association with the level of
CRP (P  0.053). Standard uptake value intensity was
also significantly correlated with the ESR (r  0.360,
P  0.026) and CRP level (r  0.355, P  0.031). The
number of vascular lesions with active 18F-FDG uptake
was associated with the ESR (r  0.511, P  0.017) and
CRP level (r  0.426, P  0.009).
Analysis of followup FDG-PET scans. Thirteen
patients underwent 15 followup FDG-PET scans. Fol-
lowup FDG-PET scans were performed to evaluate
responses to immunosuppressive treatment. At baseline,
9 patients (patients 1–9) had clinically active disease and
had at least 1 active 18F-FDG uptake lesion (visual grade
Table 2. Comparison of 18F-FDG uptake levels between patients with clinically active disease and those
with clinically inactive disease*
Clinically
active disease
(n  24)
Clinically
inactive disease
(n  14) P
Age, mean  SD years 41.7  12.7 45.3 10.1 NS
Female, no. (%) 22 (91.7) 12 (85.7) NS
Glucose, mean  SD mg/dl 93.5  14.1 92.7 10.1 NS
Visual grade, median (range) 2.5 (1–3) 1 (1–2) 0.001
SUV intensity, median (range) 1.01 (0.71–2.36) 0.79 (0.56–0.95) 0.001
Vascular lesions with active 18F-FDG uptake,
median (range) no.
4.5 (0–11) 1.72 (0–4) 0.003
* NS  not significant (see Table 1 for other definitions).
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2) on their FDG-PET scans. These patients received
moderate-to-high doses of prednisolone with methotrex-
ate. The other 4 patients (patients 35–38) had clinically
inactive disease according to the NIH criteria at base-
line; however, immunosuppressive drugs including pred-
nisolone and/or methotrexate were given to all 4 patients
because two of them (patients 35 and 36) had mild
18F-FDG uptake and two (patients 37 and 38) had active
vascular uptake on the FDG-PET scans, which sug-
gested the presence of inflammation in the arterial walls.
Table 3. Results of followup FDG-PET scans*
Patient/age/sex,
visit†
Elapsed
time from
baseline,
months
Clinical
disease
activity
ESR,
mm/hour
CRP,
mg/dl
Visual
grade‡
SUV
intensity§
Lesions with
active 18F-
FDG uptake¶ Treatment
1/37/F
1 – Yes 29 NA 3 1.25 1–3, 5, 8–11 MTX 10 mg  Pred. 60 mg
2 3 No 4 NA 2 0.97 1–6, 8 MTX 15 mg  Pred. 15 mg
2/38/F
1 – Yes 26 0.41 3 1.0 1, 2, 4–11 MTX 10 mg  Pred. 60 mg
2 7 No 38 0.39 2 0.72 5, 8, 9 MTX 15 mg  Pred. 15 mg
3/42/F
1 – Yes 70 5.38 2 1.01 1 MTX 10 mg  Pred. 60 mg
2 3 No 7 0.19 1 0.60 – MTX 15 mg  Pred. 10 mg
4/33/F
1 – Yes 50 4.91 3 1.41 1–11 MTX 10 mg  Pred. 30 mg
2 1 No 2 0.1 2 0.67 1–2 MTX 15 mg  Pred. 20 mg
5/41/F
1 – Yes 45 1.81 3 1.78 1, 3–6, 8–11 MTX 10 mg  Pred. 60 mg
2 2 No 5 0.44 2 0.77 3, 8 MTX 15 mg  Pred. 20 mg
6/45/F
1 – Yes 29 0.43 3 1.23 1–4, 6, 8 MTX 10 mg  Pred. 60 mg
2 4 No 15 0.26 1 0.75 – MTX 15 mg  Pred. 10 mg
7/56/F
1 – Yes 24 0.5 3 0.96 2, 3, 5, 6, 8 MTX 10 mg  Pred. 40 mg
2 5 No 12 0.29 2 0.83 5, 6, 8 MTX 15 mg  Pred. 10 mg
8/23/F
1 – Yes 120 2.33 3 2.36 1–11 MTX 10 mg  Pred. 60 mg
2 8 No 15 0.44 2 1.0 4, 5, 8 MTX 15 mg  Pred. 15 mg
3 33 Yes 98 1.91 3 1.33 1–9 MTX 15 mg  Pred. 60 mg
9/25/F
1 – Yes 26 1.1 2 0.90 1, 2, 8 Pred. 30 mg
2 3 Yes 8 0.46 3 1.01 1, 2, 4, 5, 8–11 MTX 10 mg  Pred. 30 mg
3 10 Yes 18 0.56 2 0.98 1, 2, 8 MTX 15 mg  Pred. 30 mg
35/48/F
1 – No 47 0.725 1 0.73 – Pred. 30 mg
2 4 No 14 0.62 1 0.65 – Pred. 10 mg
36/26/M
1 – No 4 0.21 1 0.82 – MTX 7.5 mg  Pred. 20 mg
2 6 No 2 0.1 1 0.63 – MTX 10 mg
37/45/F
1 – No 14 0.10 2 0.83 1 Pred. 20 mg
2 3 No 3 0.10 2 0.75 1 Pred. 10 mg
38/36/F
1 – No 12 0.21 2 0.71 1, 2, 6, 8 MTX 7.5 mg  Pred. 20 mg
2 10 Yes 41 0.70 3 1.12 1, 2, 6, 8 MTX 12.5 mg  Pred. 30 mg
* MTX  methotrexate; Pred.  prednisolone (see Table 1 for other definitions).
† Baseline visit is visit 1.
‡ Semiquantitative measure of 18F-FDG uptake, where 0  no vascular uptake, 1  vascular uptake less than liver uptake, 2  vascular uptake
similar to liver uptake, and 3  vascular uptake greater than liver uptake. The visual grade of a vascular ROI with maximal 18F-FDG uptake was
selected.
§ Defined as the ratio of maximal standard uptake value of a vascular ROI to the maximal standard uptake value of liver at the 1 vascular ROI with
the most intense 18F-FDG uptake.
¶ Vascular regions with visual grade values 2: 1  ascending aorta, 2  aortic arch, 3  right innominate artery, 4  right subclavian artery, 5 
right common carotid artery, 6  left common carotid artery, 7  left subclavian artery, 8  descending thoracic aorta, 9  abdominal aorta, 10 
right common iliac artery, 11  left common iliac artery.
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Followup FDG-PET scans were obtained 4.19  2.5
months (mean  SD) after the start of immunosuppres-
sive treatment (Table 3).
Followup FDG-PET scans of patients with active
disease at baseline. Eight of the 9 patients (patients 1–8)
who had clinically active disease at baseline achieved
inactive disease status in a median of 3.5 months (range
1–8 months). The decrease in visual grade (P  0.011),
standard uptake value intensity (P  0.008), and extent
of vascular uptake (P  0.028) was statistically signifi-
cant according to the Wilcoxon signed rank test on the
followup FDG-PET scans in these 8 patients. Figure 1A
shows the marked decrease in 18F-FDG uptake on the
followup FDG-PET scan after immunosuppressive
treatment.
Patient 8 experienced a disease flare at the time
of the third scan, when the visual grade, standard uptake
value intensity, and extent of active 18F-FDG uptake
increased. Patient 9 continued to have clinically active
disease despite treatment with prednisolone. In this
case, the visual grade, standard uptake value intensity,
and extent of active 18F-FDG uptake had increased at
the time of the second scan, but after more intensive
immunosuppression these 3 parameters showed a de-
crease on the third scan (Tables 3 and 4).
Followup FDG-PET scans of patients with inactive
disease at baseline. After immunosuppressive treatment,
the extent of active vascular 18F-FDG uptake and stan-
dard uptake value intensity decreased in 3 patients
(patients 35–37). These 3 patients had inactive disease at
followup, but patient 38 experienced a disease flare. The
followup FDG-PET scan in this patient showed an
increase in visual grade and standard uptake value
intensity (Figure 1B and Tables 3 and 4).
Discrepancies between FDG-PET scans and clin-
ical disease activity. The FDG-PET scan showed mild
18F-FDG uptake (visual grade 2) in 6 of 24 patients
with clinical disease activity. However, none of them
showed an 18F-FDG uptake of visual grade 0 in their
vascular region. FDG-PET showed an increased 18F-
FDG uptake (visual grade 2) in 5 of the 14 patients
without clinical disease activity. Two of these 5 patients
underwent followup FDG-PET scans. One patient (pa-
tient 37) showed a decrease in 18F-FDG uptake after
immunosuppressive treatment, and the other (patient
38) showed a worsened feature on the followup scan
despite immunosuppressive treatment. The latter pa-
tient turned out to have clinically active disease at the
time of the followup scan (Table 3).
DISCUSSION
In this study of 53 FDG-PET scans of 38 patients,
we found a significant association between 18F-FDG
uptake and clinical disease activity of TA defined by the
NIH criteria. Similarly, 18F-FDG uptake correlated well
with commonly used surrogate markers such as the ESR
and CRP level. Furthermore, our longitudinal analysis
of the followup scans demonstrated that changes in
FDG-PET scans in a given patient corresponded well to
changes in clinical disease activity.
Our results are concordant with those of previous
studies (9–14). Andrews et al reported that FDG-PET
identified active vascular lesions in 5 of 6 patients with
Figure 1. Changes in 18F-fluorodeoxyglucose (18F-FDG) uptake on followup 18F-fluorodeoxyglucose–positron emission tomography (FDG-PET)
scans. A, FDG-PET scans of patient 8 at baseline and at followup. Patient 8 improved clinically after immunosuppressive treatment. Note the marked
decrease in 18F-FDG uptake in the ascending aorta and its branches as well as in the subclavian arteries on the followup FDG-PET scan performed
8 months after treatment. B, FDG-PET scans of patient 38 at baseline and at followup. Patient 38 experienced a disease flare. Note the increase
in 18F-FDG uptake in the left common carotid artery on the followup FDG-PET scan.
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active TA, and that increased 18F-FDG uptake at base-
line decreased in all 4 patients who achieved remission
after immunosuppressive treatment (9). Kobayashi et al
reported no increased 18F-FDG uptake in patients with
inactive TA (11). Webb et al reported that FDG-PET
identified 11 of 12 patients with active TA and all 6
patients with inactive TA (14). De Leeuw et al reported
similar results in 5 patients with large-vessel vasculitis
(10). Furthermore, we observed decreases in the extent
of 18F-FDG uptake as well as standard uptake value
intensity in patients with clinically inactive disease at
baseline, according to the NIH criteria, after immuno-
suppressive treatment.
Our results contrast with those of a study by
Arnaud et al (8), which showed a lack of correlation
between 18F-FDG uptake, clinical disease activity, and
levels of markers of inflammation. They pointed out that
previous studies used various invalid criteria for active
Table 4. Comparison of visual grade scores between baseline and followup FDG-PET scans*
Patient/age/sex,
visit†
Clinical disease
activity
Localization‡ No. of lesions
with active
18F-FDG
uptakeAsc. A. A. arch Inn. A.
SCA
(R/L)
CCA
(R/L) Desc. A. Abd. A.
CIA
(R/L)
1/37/F
1 Yes 2 3 3 1/0 3/0 3 2 2/2 7
2 No 2 2 2 1/0 2/2 2 1 1/1 5
2/38/F
1 Yes 2 2 0 2/2 3/2 3 2 2/2 10
2 No 1 0 0 1/0 2/0 2 2 1/1 3
3/42/F
1 Yes 2 1 1 1/1 1/1 1 1 1/1 1
2 No 1 0 0 1/0 1/0 1 1 1/1 0
4/33/F
1 Yes 3 3 3 3/2 2/3 3 3 2/2 11
2 No 2 2 0 0/0 0/0 0 0 1/1 2
5/41/F
1 Yes 3 0 3 2/0 3/2 3 2 2/2 9
2 No 1 0 2 1/0 1/0 2 1 1/1 2
6/45/F
1 Yes 3 2 2 2/0 1/2 2 1 1/1 6
2 No 1 1 1 1/0 1/0 1 1 1/1 0
7/56/F
1 Yes 1 2 2 1/0 2/3 2 1 1/1 5
2 No 1 1 0 1/0 2/2 2 1 1/1 3
8/23/F
1 Yes 3 3 3 3/3 3/3 3 3 3/3 11
2 No 1 0 0 2/0 2/0 2 1 1/1 3
3 Yes 2 3 3 3/3 3/3 3 2 1/1 9
9/25/F
1 Yes 2 2 0 1/0 1/0 2 1 2/2 3
2 Yes 2 2 0 2/0 2/0 3 2 0/0 8
3 Yes 2 2 0 1/0 1/0 2 1 0/0 3
35/48/F
1 No 1 0 0 0/0 1/1 1 0 0/0 0
2 No 1 0 0 0/0 0/1 0 0 0/0 0
36/26/M
1 No 0 0 0 0/0 1/0 0 1 1/1 0
2 No 0 0 0 0/0 1/0 0 0 1/1 0
37/45/F
1 No 2 1 0 0/0 0/1 1 1 1/1 1
2 No 2 1 0 0/0 0/0 1 1 1/1 1
38/36/F
1 No 2 2 0 1/0 1/2 2 1 – 4
2 Yes 2 2 0 1/0 1/3 2 1 – 4
* See Table 1 for other definitions.
† Baseline visit is visit 1.
‡ Asc. A.  ascending aorta; A. arch  aortic arch; Inn. A.  innominate artery; SCA  subclavian artery; R  right; L  left; CCA  common
carotid artery; Desc. A.  descending aorta; Abd. A.  abdominal aorta; CIA  common iliac artery.
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TA and may therefore be biased. They depended exclu-
sively on clinical symptoms without markers of inflam-
mation when assessing clinical disease activity and re-
ported that the FDG-PET scan had a sensitivity of
69.2% and a specificity of 33.3% for clinically active TA.
However, among the 27 patients in their study who
underwent FDG-PET scans that showed clinically inac-
tive disease, 9 had either increased ESRs or increased
CRP levels. Arnaud et al might have underestimated the
disease activity in these patients.
Increased 18F-FDG uptake was seen in 5 patients
with clinically inactive disease. It is difficult to explain
this discrepancy because histologic examination was not
available in our study. It may reflect vascular remodeling
or atheroma. Alternatively, it could reflect residual
inflammation of the arterial wall identified in surgical
specimens from patients with clinically inactive disease
(1,2). Some of them showed a response to immunosup-
pressive treatment on the followup scan. Although in-
creased 18F-FDG uptake in patients with clinically inac-
tive disease may reflect residual inflammation, the long-
term implications of such findings and the value of
changing therapy based on such results are not known.
In contrast, 6 patients with active disease did not
show active 18F-FDG uptake. None of them, however,
showed an absence of 18F-FDG uptake. They showed
mild 18F-FDG uptake in their vascular regions. This mild
18F-FDG uptake may reveal inflammation of the arterial
wall. Pathologic confirmation or followup of these mild
18F-FDG uptake findings would be helpful in determin-
ing their clinical implications. Unfortunately, followup
FDG-PET scan was not available in these patients.
We assessed 18F-FDG uptake using various
methods in order to measure it more accurately and
comprehensively. The method of assessing 18F-FDG
uptake varied according to the study. Some studies used
semiquantitative analysis comparing the 18F-FDG up-
take of a vascular ROI with that of the liver (9,10), while
others quantified 18F-FDG uptake using methods such
as standard uptake value (11,13). We measured 18F-
FDG uptake using both semiquantitative (visual grade)
and quantitative (standard uptake value intensity) meth-
ods and checked the number of vascular lesions with
active 18F-FDG uptake to quantify the extent of disease.
We found a significant association between clinical
disease activity and 18F-FDG uptake, regardless of the
way it was measured. We used standard uptake value
intensity to quantitatively measure 18F-FDG uptake.
Standard uptake value may vary according to various
factors including serum glucose level, uptake time, ROI
geometry, and the like (20). To minimize the effects of
various confounders, we adjusted the standard uptake
value of an ROI in a vascular region with the maximal
standard uptake value of the liver, which may reduce the
effect of uptake time and serum glucose level.
Fourteen patients were receiving immunosup-
pressive drugs including glucocorticoids at the time of
the baseline FDG-PET scan. Although acute hypergly-
cemia induced by glucocorticoids was reported to reduce
18F-FDG uptake (21,22), there was no difference in
blood glucose levels between patients with active disease
and those with inactive disease on FDG-PET scans in
our study. However, little is known about the effects of
other immunosuppressive drugs on 18F-FDG uptake,
and we cannot completely exclude their potential effects.
Similar results were reported in patients with
giant cell arteritis (GCA), another type of large-vessel
vasculitis (23). Although FDG-PET could not reveal the
inflammatory changes in cranial branches of arteries
originating from the aortic arch due to their small
diameter and superficial location, FDG-PET was valu-
able in detecting inflammatory changes in the large
extracranial arteries in GCA (24,25). Thoracic vascular
18F-FDG uptake showed a sensitivity of 56%, a specific-
ity of 98%, and a PPV of 93% for the diagnosis of GCA
and polymyalgia rheumatica (26). However, questions
have been raised as to the role of FDG-PET in following
up patients with GCA, as FDG-PET was unable to
identify which patients would have relapse of their
disease (27).
Assessment of the disease activity of TA is chal-
lenging. Clinical symptoms and laboratory markers for
the assessment of disease activity of TA may not fully
reflect the actual inflammation in the arterial wall (1).
Imaging modalities such as CT, MRI, and ultrasonog-
raphy may reveal inflammatory changes of the arterial
wall, but they have several limitations in assessing the
actual disease activity of TA (3). FDG-PET scanning is
a functional imaging technique capable of quantifying
the burden of inflammation, and several studies have
shown that it correlates well with disease activity of TA.
In our study, 18F-FDG uptake in patients with active TA
showed a significant response to immunosuppressive
treatment. FDG-PET may have a role in the assessment
of disease activity of TA, especially in patients in whom
disease activity is unclear based on clinical symptoms
and laboratory markers.
Our study has several limitations. Because our
study was retrospective, it may have weaknesses such as
a selection bias and incomplete or suboptimal data
collection. However, our series consisted of consecutive
patients who agreed to undergo a PET scan. Prospective
FDG-PET IN TA 873
confirmation of our findings would be valuable. Second,
we used the NIH criteria as a tool for assessing the
disease activity of TA. Currently, there is no definitive
gold standard for assessing disease activity in TA (28).
Although it is worthwhile to note that these criteria have
also been used in several other studies (9,29,30), they
are, nonetheless, neither standardized nor validated as
assessments of clinical disease activity in TA. Therefore,
further research is needed to develop a validated set of
outcome measures for use in clinical trials of TA (28).
Third, not all the patients underwent regular angio-
graphic assessment, which is a component of the NIH
criteria for active disease in TA. In addition, concomi-
tant angiography at times of FDG-PET scan was not
available in this study. Finally, we were not able to
perform followup FDG-PET scans in all the patients.
Followup FDG-PET scans were performed only in pa-
tients who agreed to undergo followup imaging.
To the best of our knowledge, our study is the
largest in terms of the number of patients (n  38) and
the number of FDG-PET scans (n  53). Although
previous studies suggested the usefulness of FDG-PET,
they enrolled smaller numbers of patients to support the
value of FDG-PET due to the rarity of the disease. We
assessed the association between 18F-FDG uptake, clin-
ical disease activity, and markers of inflammation. Al-
though our results alone may not be sufficient to suggest
the superiority of FDG-PET over clinical disease activity
and markers of inflammation, its substantial correlation
with these existing variables gives support to the poten-
tial value of this noninvasive imaging modality in the
diagnosis and management of TA. Of note is the diffi-
culty in obtaining pathologic samples from TA patients,
because TA involves large vessels. In this respect, a
prospective followup study would be helpful to investi-
gate the usefulness of FDG-PET for the assessment of
disease activity in patients with TA.
In conclusion, our data suggest that 18F-FDG
uptake is associated with clinical disease activity and
markers of inflammation, and that FDG-PET reflects
changes in clinical disease activity in patients with TA.
FDG-PET may be a useful tool for aiding in the
assessment of disease activity in patients with TA.
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